FindMyKOL
Clinical trialNCT06735820RecruitingPhase 1/PHASE2Interventional

Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST

SponsorAeRang KimEnrollment45Atypical NeurofibromaMalignant Peripheral Nerve Sheath Tumor (MPNST)Neurofibromatosis 1 (NF1)
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a phase 0/1/2, multi-site study to evaluate the MEK inhibitor Selumetinib with the MDM2 Inhibitor APG-115 in patients with Neurofibromatosis Type 1 and pre-malignant and malignant peripheral nerve sheath tumors
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Children'S National Hospital

    Washington D.C., District of Columbia, United States

    Recruiting
  • Ut Southwestern Medical Center

    Dallas, Texas, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AlrizomadlinSelumetinib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Jun 2026
Primary completion
1 Oct 2027
Completion
1 Oct 2028
Last update posted
27 Jul 2026
Registered enrollment
45
Registry id
NCT06735820
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.